MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
About Opthea
Authorized for release to ASX by Fred Guerard, CEO
Investor Enquiries
PJ Kelleher
LifeSci Advisors
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media
Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399
Email: info@opthea.com
